CTOs on the Move

Renovacor

www.renovacor.com

 
Renovacor is a preclinical gene therapy company developing a pipeline of innovative and proprietary AAV based gene therapies for BAG3 gene mutation-associated diseases in areas of high unmet medical need. Renovacor`s therapeutic focus is initially on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Kumar Dhanasekharan
Senior Vice President of Technical Operations Profile

Funding

Renovacor raised $11M on 08/15/2019

Similar Companies

Acrometrix

Acrometrix is a Benicia, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CereVasc

The CereVasc eShuntâ„¢ device is intended to improve patient outcomes and redefine the treatment of communicating hydrocephalus.

Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical corporation based in Indianapolis, Indiana, with a history of nearly 150 years. Founded in 1876 by Colonel Eli Lilly, the company has grown to become one of the largest pharmaceutical enterprises in the world, employing over 42,900 people as of 2023. Lilly focuses on biomedical research, drug discovery, and manufacturing, with a diverse portfolio that includes treatments for diabetes, oncology, neuroscience, and immunology. Lilly pioneered the first commercially available insulin product in 1923 and continues to innovate with modern offerings like Trulicity and Mounjaro for diabetes management. The company also develops drugs such as Verzenio for breast cancer and Zyprexa for psychiatric disorders. With a strong emphasis on research and development, Lilly is recognized for its commitment to improving drug accessibility and patient care through partnerships with healthcare providers and systems worldwide.

Virobay

Virobay is focused on the development and commercialization of novel drugs through the utilization of small molecule inhibitors of cysteine proteases, a diverse class of enzyme proteases, for a variety of conditions, including neuropathic pain, autoimmune diseases and fibrosis.  The foundation of Virobay's proprietary cathepsin platform and the Virobay management team were spun-out from Celera Genomics, which was then a leader in cathepsin research. Virobay's clinical pipeline currently includes product candidates in neuropathic pain, dermatology, autoimmune disease and fibrosis.

Intrexon Corporation

Intrexon Corporation is a privately held synthetic biology company that employs modular DNA control systems to enhance capabilities, improve safety and lower cost in human therapeutics, protein production, industrial products, agricultural biotechnology, and animal science.